Abstract: A method of processing of a biological sample containing multiple metabolites is described The method comprising the steps of pre-treating the biological sample with a metabolite extraction solvent to provide a pre-treated sample, separating a first aliquot of the pre-treated sample by reverse phase liquid chromatography (RPLC) to provide a first eluent containing resolved hydrophobic metabolites, and separating a second aliquot of the pre-treated sample by hydrophilic interaction liquid interaction chromatography (HILIC) to provide a second eluent containing resolved hydrophilic metabolites. The first and second eluents are assayed using targeted tandem mass spectroscopy operated in multiple reaction monitoring mode. Each liquid chromatography step(LC) is directly hyphenated with the tandem mass spectrometry (MS/MS) into a single LC-MS/MS analysis. The extraction solvent typically comprises methanol, isopropanol and an acetate buffer.

Abstract: A system and method of generating a model M that can detect or predict the predisposition to an outcome, for example a person's predisposition to developing a health condition such as preeclampsia, with a positive or/and negative predictive value better or equal to a predefined predictive value target, where the method factors in the impact of prevalence on test performance. The system and method employ an iterative population segregation methodology, involving at least two population segregations steps in which each step, independently, employs a probability-defined model. The first segregation step is selected from one of a rule-in probability defined model and a rule-out probability defined model, and the second segregation step is selected from the other of a rule-in probability defined model and a pile-out probability defined model.

Abstract: A computer implemented method of early prediction of risk of a pregnancy outcome in a pregnant woman, comprising the steps of: inputting into a computational model values for a panel of a plurality of preeclampsia specific biomarkers comprising at least one metabolite, and optionally at least one protein or clinical risk factor, selected from Table 1, in which the values are obtained from the pregnant woman early in pregnancy; selecting a subset of inputted values comprising a value for at least one metabolite and optionally at least one protein or clinical risk factor value, based on a selected pregnancy outcome selected from pre-term preeclampsia, term preeclampsia and all preeclampsia; calculating a predicted risk of the selected pregnancy outcome based on the subset of inputted values; and outputting the predicted risk of the pregnancy outcome for the pregnant woman.

Abstract: A method of processing of a biological sample containing multiple metabolites is described The method comprising the steps of pre-treating the biological sample with a metabolite extraction solvent to provide a pre-treated sample, separating a first aliquot of the pre-treated sample by reverse phase liquid chromatography (RPLC) to provide a first eluent containing resolved hydrophobic metabolites, and separating a second aliquot of the pre-treated sample by hydrophilic interaction liquid interaction chromatography (HILIC) to provide a second eluent containing resolved hydrophilic metabolites. The first and second eluents are assayed using targeted tandem mass spectroscopy operated in multiple reaction monitoring mode. Each liquid chromatography step(LC) is directly hyphenated with the tandem mass spectrometry (MS/MS) into a single LC-MS/MS analysis. The extraction solvent typically comprises methanol, isopropanol and an acetate buffer.

Abstract: A method of processing of a biological sample containing multiple metabolites is described The method comprising the steps of pre-treating the biological sample with a metabolite extraction solvent to provide a pre-treated sample, separating a first aliquot of the pretreated sample by reverse phase liquid chromatography (RPLC) to provide a first eluent containing resolved hydrophobic metabolites, and separating a second aliquot of the pre-treated sample by hydrophilic interaction liquid interaction chromatography (HILIC) to provide a second eluent containing resolved hydrophilic metabolites. The first and second eluents are assayed using targeted tandem mass spectroscopy operated in multiple reaction monitoring mode. Each liquid chromatography step (LC) is directly hyphenated with the tandem mass spectrometry (MS/MS) into a single LC-MS/MS analysis. The extraction solvent typically comprises methanol, isopropanol and an acetate buffer.

Abstract: A method of early detection of risk of pre-eclampsia in a pregnant woman comprises the steps of determining the blood pressure and body mass index (BMI) of the pregnant woman, and optionally sex of the fetus, at 8 to 24 weeks of pregnancy, comparing the BMI with a reference BMI, and comparing the blood pressure input with a reference blood pressure, and providing a risk of pre-eclampsia and in particular term or pre-term pre-eclampsia based on the comparison.

Abstract: A computer implemented method of early prediction of risk of pre-eclampsia in a pregnant obese woman is described. The method comprises the steps of inputting abundance values for a panel of obese pregnancy specific metabolite biomarkers obtained from an assayed biological sample into a computational model, in which the biological sample is obtained from an obese pregnant woman at 8 to 24 weeks of pregnancy, and inputting a patient parameter for the pregnant obese woman into the computational model selected from at least one of ethnicity, risk of gestational diabetes, fetal sex, number of pregnancies and level of obesity. The computational model is configured to select a subset comprising at least two of the obese pregnancy specific metabolite biomarkers based on the patient parameter input, correlate abundance values for the subset of obese pregnancy specific metabolite biomarkers with risk of pre-eclampsia, and output a predicted risk of pre-eclampsia for the pregnant obese woman.

Abstract: A system and method of generating a model M that can detect or predict the predisposition to an outcome, for example a person's predisposition to developing a health condition such as preeclampsia, with a positive or/and negative predictive value better or equal to a predefined predictive value target, where the method factors in the impact of prevalence on test performance. The system and method employ an iterative population segregation methodology, involving at least two population segregations steps in which each step, independently, employs a probability-defined model. The first segregation step is selected from one of a rule-in probability defined model and a rule-out probability defined model, and the second segregation step is selected from the other of a rule-in probability defined model and a rule-out probability defined model.

Abstract: A computer implemented method of early prediction of risk of a pregnancy outcome in a pregnant woman, comprising the steps of: inputting into a computational model values for a panel of a plurality of preeclampsia specific biomarkers comprising at least one metabolite, and optionally at least one protein or clinical risk factor, selected from Table 1, in which the values are obtained from the pregnant woman early in pregnancy; selecting a subset of inputted values comprising a value for at least one metabolite and optionally at least one protein or clinical risk factor value, based on a selected pregnancy outcome selected from pre-term preeclampsia, term preeclampsia and all preeclampsia; calculating a predicted risk of the selected pregnancy outcome based on the subset of inputted values; and outputting the predicted risk of the pregnancy outcome for the pregnant woman.

Abstract: The application discloses new test panels comprising biomarkers and clinical parameters, for the prediction, diagnosis, prognosis and/or monitoring of hypertensive disorders of pregnancy and particularly preeclampsia; and related methods, uses, kits and devices.

Abstract: The application discloses new test panels comprising biomarkers and clinical parameters, for the prediction, diagnosis, prognosis and/or monitoring of hypertensive disorders of pregnancy and particularly preeclampsia; and related methods, uses, kits and devices.

Abstract: The invention provides novel fragments of proBNP and NTproBNP, particularly useful in prognosing or diagnosing acute heart failure, chronic heart failure or sepsis.